BAIYUNSHAN PH's Subsidiary Receives Approval for Supplemental Applications of Cefuroxime Sodium and Candesartan Cilexetil Tablets
Stock News
May 11
BAIYUNSHAN PH (00874) announced that its subsidiary, Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd. (Tianxin Pharmaceutical), has recently received the "Drug Supplemental Application Approval Notice" from the National Medical Products Administration for Cefuroxime Sodium for Injection 0.5g (calculated as C16H16N4O8S) and Candesartan Cilexetil Tablets 4mg. The approval indicates that the impurity pharmaceutical research for these drugs has been recognized, which is expected to enhance the quality control capabilities and market competitiveness of these products. This approval is not expected to have a significant impact on the company's current financial performance.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.